Following KEYNOTE-001, KEYNOTE-010 was a phase II/III clinical trial that randomized 1034 patients to pembrolizumab (2 or 10 mg/kg every 3 weeks) vs. docetaxel (75 mg/m2) for PD-L1-positive NSCLC that progressed after platinum-based chemotherapy or a tyrosine kinase inhibitor (TKI) for those with an EGFR-sensitizing mutation or ALK gene rearrangement [24]. This evidence concerns the gene ALK and non-small cell lung carcinoma.